0000899243-20-026192.txt : 20200923
0000899243-20-026192.hdr.sgml : 20200923
20200923191056
ACCESSION NUMBER: 0000899243-20-026192
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200731
FILED AS OF DATE: 20200923
DATE AS OF CHANGE: 20200923
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lubner David Charles
CENTRAL INDEX KEY: 0001572000
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 201193127
MAIL ADDRESS:
STREET 1: C/O TETRAPHASE PHARMACEUTICALS, INC.
STREET 2: 480 ARSENAL STREET, SUITE 110
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-07-31
0
0001818794
Dyne Therapeutics, Inc.
DYN
0001572000
Lubner David Charles
C/O DYNE THERAPEUTICS, INC.
830 WINTER STREET
WALTHAM
MA
02451
1
0
0
0
Common Stock
2020-09-21
4
C
0
53625
A
53625
D
Stock Option (right to buy)
5.54
2020-07-31
4
A
0
11156
0.00
A
2030-07-30
Common Stock
11156
11156
D
Stock Option (right to buy)
5.54
2020-07-31
4
A
0
14444
0.00
A
2030-07-30
Common Stock
14444
14444
D
Series B Preferred Stock
2020-08-07
4
P
0
177872
2.811
A
Common Stock
53625
177872
D
Series B Preferred Stock
2020-09-21
4
C
0
177872
0.00
D
Common Stock
53625
0
D
On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The option was granted on July 31, 2020. The shares underlying the option are scheduled to vest over four years in equal quarterly installments through July 31, 2024, provided that no shares shall vest prior to March 19, 2021.
The option was granted on July 31, 2020. The shares underlying the option are scheduled to vest over four years in equal quarterly installments through July 31, 2024, provided that no shares shall vest prior to March 19, 2021.
The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
/s/ Richard Scalzo, Attorney-in-Fact
2020-09-23